Gut-brain chemokine changes in portal hypertensive rats

Digestive Diseases and Sciences

Volumn 56, Issue 8, 2011, Pages 2309-2317

  Merino, Joaquin ^a   Aller, Maria Angeles ^a   Rubio, Sandra ^b   Arias, Natalia ^c   Nava, Maria Paz ^a   Loscertales, Maria ^d   Arias, Jaime ^a   Arias, Jorge Luis ^c  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c UNIVERSITY OF OVIEDO   (Spain)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Chemokines; CXCR1 Fractalkine; CXCR4 SDF1 alpha; Hepatic encephalopathy; Neuroinflammation; Rat

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; CHEMOKINE RECEPTOR CXCR4; FRACTALKINE; STROMAL CELL DERIVED FACTOR 1ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CONTROLLED STUDY; EXPERIMENTAL RAT; HEPATIC ENCEPHALOPATHY; HIPPOCAMPUS; ILEUM; INFLAMMATION; LIVER; MALE; MESENTERY LYMPH NODE; NONHUMAN; PORTAL HYPERTENSION; PORTAL HYPERTENSIVE ENCEPHALOPATHY; PORTAL VEIN; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VEIN LIGATION;

ANIMALS; BRAIN; CEREBELLUM; CHEMOKINE CX3CL1; CHEMOKINE CXCL12; CHEMOKINES; GASTROINTESTINAL TRACT; HIPPOCAMPUS; HYPERTENSION, PORTAL; HYPERTENSIVE ENCEPHALOPATHY; LYMPH NODES; MALE; MESENTERY; RATS; RATS, WISTAR; RECEPTORS, CHEMOKINE; RECEPTORS, CXCR4;

EID: 79960968948     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-011-1625-y     Document Type: Article

References (63)

1. Zafirova Z, O'Connor M. Hepatic encephalopathy: current management strategies and treatment, including management and monitoring of cerebral edema and intracraneal hypertension in fulminant hepatic failure. Curr Opin Anaesthesiol. 2010;23:121-127.
2. Ferenci P, Lockwood A, Muller K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis and quantification. Final report of the working party at the 11th World Congress of Gastroenterology, Vienna 1998. Hepatology. 2002;35:716-721. (Pubitemid 34183979)
3. Sundaram V, Shaikh OS. Hepatic encephalopathy: Physiopathology and emerging therapies. Med Clin N Am. 2009;93:819-836.
4. Mínguez B, García-Pagán JC, Bosch J, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology. 2006;46:707-714.
5. Yadav SK, Srivastava A, Srivastava A, et al. Encephalopathy assessment in children with extra-hepatic portal vein obstruction with MR, psychometry and critical flicker frequency. J Hepatol. 2010;52:348-354.
6. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Pharmacol. 1985;248:G618-G625. (Pubitemid 15232794)
7. Abraldes JG, Pasarin M, García-Pagán JC. Animal models of portal hypertesion. World J Gastroenterol. 2006;12:6577-6584.
8. Aller MA, Méndez M, Nava MP, López L, Arias JL, Arias J. The value of microsurgery in liver research. Liver Int. 2009;29:1132-1140.
9. Aller MA, Méndez M, Nava MP, et al. Portal surgery: Portosystemic shunts and portal hypertension. In: Aller MA, Arias J, eds. Microsurgery in Liver Research. Bentham Scientific e-books. 2009;117-136.
10. Shawcross D, Jalan R. The physiopathological basis of hepatic encephalopathy: central role for ammonia and inflammation. Cell Mol Life Sci. 2005;62:2295-2304. (Pubitemid 41500545)
11. Shawcross DL, Wright G, Olde Damink SWM, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab Brain Dis. 2007;22:125-138. (Pubitemid 46354829)
12. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2010;51:1062-1069.
13. Arias JL, Aller MA, Sánchez-Patán F, Arias J. The inflammatory bases of hepatic encephalopathy. Eur J Gastroenterol Hepatol. 2006;18:1297-1310. (Pubitemid 44737062)
14. Aller MA, Arias JL, Cruz A, Arias J. Inflammation: a way to understanding the evolution of portal hypertension. Theor Biol Med Model. 2007;4:44-69.
15. Bendall L. Chemokines and their receptors in disease. Histol Histopathol. 2005;20:907-926. (Pubitemid 40932609)
16. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med. 2006;354:610-621. (Pubitemid 43209108)
17. Ubogu EE, Cossoy MB, Ransohoff RM. The expression and function of chemokines involved in CNS inflammation. Trends Pharmacol Sci. 2006;27:48-55. (Pubitemid 43063124)
18. Monterde G, Rodríguez-Fabián G, Vara E, et al. Increased plasma levels of corticosterone and prolactine and decreased T3 and T4 levels in short-term prehepatic portal hypertension in rats. Dig Dis Sci. 2000;45:1865-1871.
19. Paxinos G, Watson C. The Rat Brain In Stereotaxic Coordinates. Compact 2nd Edition. London: Academic Press; 1997.
20. Lynch MA, Voss KL. Presynaptic changes in long-term potentiation: elevated synaptosomal calcium concentration and basal phosphoinositide turnover in dentate gyrus. J Neurochem. 1991;1:113-118. (Pubitemid 21901937)
21. Bradford MM. A rapid and sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal Biochem. 1976;72:248-254.
22. Merino JJ, Cordero MI, Sandi C. Regulation of hippocampal cell adhesion molecules NCAM and L1 by contextual fear conditioning is dependent upon time and stressor intensity. Eur J Neurosci. 2000;12:3283-3290.
23. Sandi C, Merino JJ, Cordero MI, Touyarot K, Venero C. Effects of chronic stress on contextual fear conditioning and the hippocampal expression of the neural cell adhesion molecule, its polysialylation, and L1. Neuroscience. 2001;102:329-339. (Pubitemid 32126487)
24. Coelho AL, Hogaboam CM, Kunkel SL. Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 2005;16:553-560. (Pubitemid 41505516)
25. Aller MA, Arias JL, Arias J. The mast cell integrates the splanchnic and systemic inflammatory response in portal hypertension. J Transl Med. 2007;5:44-59.
26. Díez-Arias JA, Aller MA, Palma MD, et al. Increased duodenal mucosa infiltration by mast cells in rats with portal hypertension. Dig Surg. 2001;18:34-40. (Pubitemid 32217858)
27. Llamas MA, Aller MA, Marquina D, Nava MP, Arias J. Bacterial translocation to mesenteric lymph nodes increases in chronic portal hypertensive rats. Dig Dis Sci. 2010;55:2244-2254.
28. Metz M, Grimbaldeston MA, Nakae S, Piliponsky AM, Tsai M, Galli SJ. Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev. 2006;217:304-328.
29. Niess JH, Brand S, Gu X, et al. CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science. 2005;307:254-258. (Pubitemid 40116240)
30. Alonso MJ, Aller MA, Corcuera MT, et al. Progressive hepatocytic fatty infiltration in rats with prehepatic portal hypertension. Hepatogastroenterology. 2005;52:541-546. (Pubitemid 40469464)
31. Simpson KJ, Henderson NC, Bone-Larson CL, Lukacs NW, Hogaboam CM, Kunkel SL. Chemokines in the pathogenesis of liver disease: so many players with poorly defined roles. Clin Sci. 2003;104:47-63. (Pubitemid 36249923)
32. Palma MD, Aller MA, Vara E, et al. Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rat. Cytokine. 2005;31:213-226. (Pubitemid 40967904)
33. Sánchez-Patán F, Anchuelo R, Aller MA, et al. Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome? Lipids Health Dis. 2008;7:4-13.
34. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005;23:879-894. (Pubitemid 41170944)
35. Kasiyanov A, Fujii N, Tamamura H, Xiong H. Modulation of network-driven, GABA-mediated giant depolarizing potentials by SDF-1alpha in the developing hippocampus. Dev Neurosci. 2008;30:285-292.
36. Barbieri F, Bajetto A, Porcile C, Pattarozzi A, Schettini G, Florio T. Role of stromal cell-derived factor 1 (SDF1/CXCL12) in regulating anterior pituitary function. J Mol Endocrinol. 2007;38:383-389. (Pubitemid 46723254)
37. Guerin E, Sheridan C, Assheton D, et al. SDF-1-alpha is associated with VEGFR-2 in human choroidal neovascularization. Microvasc Res. 2008;75:302-307.
38. Guyon A, Nahon J-L. Multiple actions of the chemokine stromal cell-derived factor-1α on neuronal activity. J Mol Endocrinol. 2007;38:365-376. (Pubitemid 46723252)
39. Bertollini C, Ragozzino D, Gross C, Limatola C, Eusebi F. Fractalkine/CX3CL1 depresses central synaptic transmission in mouse hippocampal slices. Neuropharmacology. 2006;51:816-821. (Pubitemid 44286937)
40. Butterworth RF. Pathogenesis of hepatic encephalopathy: new insights from neuroimaging and molecular studies. J Hepatol. 2003;29:278-285. (Pubitemid 36920567)
41. Weissenborn K, Bokemeyer M, Ahl B, et al. Functional imaging of the brain in patients with liver cirrhosis. Metab Brain Dis. 2004;19:269-280. (Pubitemid 39361188)
42. Weissenborn K, Giewekemeyer K, Heidenreich S, Bokemeyer M, Berding G, Ahl B. Attention, memory and cognitive function in hepatic encephalopathy. Metab Brain Dis. 2005;20:359-367. (Pubitemid 43029808)
43. Lores-Arnaiz S, Perazzo JC, Prestifilipo JP, et al. Hippocampal mitochondrial dysfunction with decreased mtNOS activity in prehepatic portal hypertensive rats. Neurochem Int. 2005;47:362-368. (Pubitemid 40968020)
44. Acosta GB, Fernández MA, Rosello DM, Tomaro ML, Balestrasse K, Lemberg A. Glutamine synthetase activity and glutamate uptake in hippocampus and frontal cortex in portal hypertensive rats. World J Gastroenterol. 2009;15:2893-2899.
45. Nikonenko AG, Radenovic L, Andjus PR, Skibo GG. Structural features of ischemic damage in the hippocampus. Anat Rec. 2009;292:1914-1921.
46. Méndez M, Méndez-López M, López L, et al. Spatial memory alterations in three models of hepatic encephalopathy. Behav Brain Res. 2008;188:32-40.
47. Méndez M, Méndez-López M, López L, Aller MA, Arias J, Arias JL. Working memory impairment and reduced hippocampal and prefrontal cortex c-Fos expression in a rat model of cirrhosis. Physiol Behav. 2008;95:302-307.
48. Santin LJ, Rubio S, Begega A, Arias JL. Effects of mammillary body lesions on spatial reference and working memory tasks. Behav Brain Res. 1999;102:137-150. (Pubitemid 29314575)
49. Méndez M, Méndez-López M, López L, Aller MA, Arias J, Arias JL. Mammillary body alterations and spatial memory impairment in Wistar rats with thioacetamide-induced cirrhosis. Brain Res. 2008;1233:185-195.
50. Kerschensteiner M, Meinl E, Hohlfeld R. Neuro-immune crosstalk in CNS diseases. Neuroscience. 2009;158:1122-1132.
51. Mrak RE, Griffin WS. Glia and their cytokines in progression of neurodegeneration. Neurobiol Aging. 2005;26:349-354. (Pubitemid 40082718)
52. Monje ML, Toda H, Palmer TD. Inflammatory blockade restores adult hippocampal neurogenesis. Science. 2003;302:1760-1765. (Pubitemid 37505739)
53. De Haas AH, Van Weering HRJ, De Jong EK, Boddeke HWGM, Biber KPH. Neuronal chemokines: Versatile messengers in central nervous system cell interaction. Mol Neurobiol. 2007;36:137-151. (Pubitemid 351360343)
54. 3CL-1-mediated neuroprotection and neuromodulation. J Immunol. 2008;180:7590-7596.
55. Wikgren J, Nokia MS, Penttonen M. Hippocampo-cerebellar theta band phase synchrony in rabbits. Neuroscience. 2010;165:1538-1545.
56. Leuner B, Gould E, Shors TJ. Is there a link between adult neurogenesis and learning? Hippocampus. 2006;16:216-224.
57. Lu M, Grove EA, Miller RJ. Abnormal development of the hippocampal dentate gyrus in mice lacking the CXCR4 chemokine receptor. PNAS. 2002;99:7090-7095. (Pubitemid 34526260)
58. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998;393:595-599. (Pubitemid 28319251)
59. Martino G. How the brain repairs itself: new therapeutic strategies in inflammatory and degenerative CNS-disorders. Lancet Neurol. 2004;3:372-378. (Pubitemid 38648859)
60. Martell M, Coll M, Ezkurdia N, Raurell I, Genesca J. Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol. 2010;2:208-220.
61. Meucci O, Fatatis A, Simen AA, Miller RJ. Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. PNAS. 2000;97:8075-8080. (Pubitemid 30460775)
62. Juremalm M, Nilsson G. Chemokine receptor expression by mast cells. Chem Immunol Allergy. 2005;87:130-144. (Pubitemid 43093184)
63. Bischoff SC. Physiological and physiopathological functions of intestinal mast cells. Semin Immunopathol. 2009;31:185-205.